$1.030
-0.713 (-69.25%)收盤時
- 最高
- 3.420
- 開盤
- 3.340
- 成交量加權均價
- 1.76
- 成交量
- 1.22M
- 市值
- —
- 最低
- 0.840
- 成交金額
- 2.16M
- 企業價值/稅息折舊攤銷前利潤(TTM)
- 0.00
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
AI 分析 of ENvue Medical Inc (FEED)
賣出ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.
估值指標
事件時間軸
資訊
7.509-09NewsfilterENvue Resumes Commercial Shipments of PainShield
8.509-02NewsfilterENvue Medical to Showcase Navigation Platform at Vizient Innovative Technology Exchange
8.508-28NASDAQ.COMENvue Medical Announces 1-for-12 Reverse Stock Split
8.508-28NewsfilterENvue Medical Announces Reverse Stock Split Effective September 1, 2026
8.508-12NewsfilterENvue Medical Secures $50 Million Equity Facility
FEED 常見問題 —— 由 Alphio AI 解答
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. It operates in the Healthcare sector.
ENvue Medical, Inc. (FEED) is not a good buy right now due to its extremely low price of $1.03, a staggering year-to-date change of -96.50%, and an RSI of 7.252 indicating oversold conditions. The company has also reported a gross margin of -111.30% in Q2 2026, highlighting severe profitability issues. The main risk is its recent performance, with a 5-day change of -75.93%, indicating continued downward pressure on the stock.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
- Bitcoin Bear Market 2026: Why BTC Fell Below $70K and How Investors Can Manage Crypto RiskBitcoin is about 45% below its $126K peak as Fed hikes, 5% yields and ETF outflows bite. See how the 2026 bear market compares and how to manage crypto risk.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。